Is Ponatinib included in medical insurance?

Ponatinib (Ponatinib) is a cancer drug used to treat adults with the following types of leukemia (cancer of the white blood cells), including chronic myelogenous leukemia (CML) in different stages, such as chronic phase, accelerated phase, and blast phase. It is also used to treat acute lymphoblastic leukemia (ALL) in patients who are "Philadelphia chromosome positive" (Ph+), meaning that some of the patient's genes have been rearranged to form a special chromosome called the Philadelphia chromosome, leading to the development of leukemia.

Ponatinib is used in patients who are intolerant or unresponsive to dasatinib (in patients with CML or ALL) or nilotinib (in patients with CML), two other cancer drugs in the same class, and for whom subsequent treatment with imatinib (the third such drug) is considered inappropriate. It is also used in patients who have a genetic mutation called the "T315I mutation" that makes them resistant to treatment with imatinib, dasatinib or nilotinib.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult the medical consultant of Yaode.